Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 05 2023 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that data for EDP-235, its
lead 3CL protease inhibitor specifically designed as an oral,
once-daily treatment for COVID-19, and EDP-323, its L-protein
inhibitor in development for the treatment of respiratory syncytial
virus (RSV), will be presented at the 33rd European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID) being held
April 15-18 both virtually and at the Bella Center Copenhagen in
Copenhagen, Denmark.
Poster Presentations: Date:
Monday, April 17, 2023 Time: 12:00 – 1:30 p.m. Central
European Summer Time (CEST) Session Title: 12e. Drug
development and treatment modalities (including in vitro, animal,
clinical trials, resistance) Poster Number: P2633
Title: “EDP-235, a Potent, Once-Daily, Oral Antiviral,
Demonstrates Potential for Treatment and Prevention of Long COVID”
Presenter: Yang Li, Ph.D.
Date: Monday, April 17, 2023 Time: 12:00 – 1:30
p.m. CEST Session Title: 1c. Influenza and respiratory
viruses (including diagnostics and epidemiology, antiviral drugs,
vaccines, treatment and susceptibility/resistance) Poster
Number: P2844 Title: “Pharmacokinetics of EDP-323, a
Potent, Once-Daily, Oral Antiviral Treatment for Respiratory
Syncytial Virus” Presenter: Lisha Xu
Posters will be available to view on the conference platform
during the conference. Further information about ECCMID 2023 can be
found here.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections. Enanta’s
research and development programs include clinical candidates for
the following disease targets: respiratory syncytial virus (RSV),
SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also
conducting research on a single agent targeting both RSV and human
metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is part of one of the leading treatment
regimens for curing chronic HCV infection and is sold by AbbVie in
numerous countries under the tradenames MAVYRET® (U.S.) and
MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit
www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230405005224/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024